Phase
Condition
Mitochondrial Diseases
Treatment
Nanosensor
Clinical Study ID
Ages 18-65 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Inclusion Criteria for Healthy Controls
Males and females, between the ages of 18 and 65 years, inclusive
Provide informed consent for study participation; able to understand andcomplete the protocol
Able to ambulate independently
Able to perform bicycle ergometry
Inclusion Criteria for Mitochondrial Myopathy (MM) Cases
Males and females, between the ages of 18 and 65 years, inclusive
Provide informed consent for study participation; able to understand and completethe protocol
Genetically-confirmed MM as defined by a diagnosis of primary mitochondrial disease (PMD) with predominant symptoms of myopathy as expressed by exercise intolerance andmuscle weakness and fatigue.
Previously enrolled (or will enroll) in Children's Hospital of Philadelphia (CHOP)Institutional Review Board (IRB) study #08-006177 (Falk, PI) or CHOP IRB #16-013364 (Zolkipli, PI)
Able to ambulate independently
Able to perform bicycle ergometry
Exclusion
Exclusion Criteria:
Subjects will be excluded if any of the following apply:
Unable to provide informed consent and complete all study procedures, includingergometry
Non-ambulatory or unable to ambulate independently
Pregnant
Within 1 month of a recent hospital admission due to acute illness
Have severe cardiac disease as defined by an ejection fraction of less than 35% andNew York Heart Association Functional Classification Class III; or severe pulmonarydisease as defined by the need for supplemental O2 therapy or daytime ventilatorysupport
Have a tracheostomy
Have a known bleeding disorder and/or family history (first-degree relative) with aknown bleeding disorder
Daily intake of aspirin or any other anti-platelet therapy which cannot betemporarily discontinued for medical reasons
a) Have known or suspected congenital or acquired immune deficiency; b) concurrentuse of immunosuppressive drugs, including corticosteroids; c) past history ofrecurrent (more than 6 times per year) severe (required hospitalization) skin orsoft tissue infections; d) history of infection or delayed wound healing aftersurgery or biopsy; e) known history of neutropenia with absolute neutrophil countless than 500/mm3
Undergo chronic steroid treatment as defined by daily oral intake (for more than 1month) or have existing untreated endocrinopathies, such as hypothyroidism thatcaused acquired myopathy
Prone to hypertrophic scars and keloids
Have any other known inherited myopathy, such as Duchenne muscular dystrophy orcongenital myopathy
Known allergy to lidocaine
Have a cognitive impairment that may prevent the ability to complete studyprocedures
Unable to comply with the requirements of the study protocol and/or unsuitable forthe study for any reason, in the opinion of the principal investigator
Individuals from vulnerable populations (e.g., prisoners/detainees)
Participants who are unable to speak and/or read English (as participants will berequired to be proficient to complete study procedures)
Employed by the U.S. Department of Defense, including U.S. military personnel
Study Design
Study Description
Connect with a study center
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania 19104
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.